Phase
Condition
N/ATreatment
N/AClinical Study ID
Ages < 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients diagnosed with Central Precocious Puberty presenting an indication toundertake treatment with GnRH analogue: Appearance of secondary sexualcharacteristics (thelarche or gonadarche) before the age of 8 for females and 9 formales; Acceleration of the rate of statural growth and advancement of bone age oneyear older than the chronological age; LH peak > 5 IU/L on GnRH test and alongitudinal uterine diameter > 36 mm in females, with or without the appearance ofendometrial rhyme;
Age at onset of entral Precocious Puberty between 2 and 8 years (females) or between 2 and 9 years (males);
Age at enrollment < 18 years;
Follow-up of at least 12 months;
Obtaining informed consent from parents/legal guardian of peduatric patients.
Exclusion
Exclusion Criteria:
Isolated telarche and/or pubarche;
Peripheral forms of precocious puberty;
Patients diagnosed with primary organic Central Precocious Puberty due to tumour- ornon-tumour-causing hypothalamic lesions.
Study Design
Study Description
Connect with a study center
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bolgona 40138
ItalyActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.